(9S)-9-dihydroerythromycin A | 63864-45-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (9S)-9-dihydroerythromycin A
• 英文别名: (9S)-9-dihydroerythromycin；9,9-dihydro-erythromycin A；9-(S)-dihydroerythromycin；(9S)-dihydroerythromycin；9-dihydroerythromycin A；Dihydroerythromycin；(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,10,12,13-tetrahydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
• CAS: 63864-45-9
• 化学式: C₃₇H₆₉NO₁₃
• 分子量: 735.954
• InChiKey: YGXCJEZVERXINS-JCTYMORFSA-N

物化性质

• 熔点：
  132-134 °C(Solv: isopropanol (67-63-0); water (7732-18-5))
• 沸点：
  819.3±65.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  51
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  197
• 氢给体数：
  6
• 氢受体数：
  14

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  红霉素	erythromycin	114-07-8	C37H67NO13	733.938
  (9S)-9-氨基-9-脱氧乙琥红霉素	erythromycylamine	26116-56-3	C37H70N2O12	734.969
  ——	erythromycinimine	30760-16-8	C37H68N2O12	732.953
  ——	(9S)-9-dihydro-9,11-O-isopropylidene-5-O-(2-O-(methoxycarbonyl)-β-D-desosaminyl)erythronolide	138505-35-8	C34H61NO12	675.858

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	9-dihydro-N-desmethylerythromycin A	654076-77-4	C36H67NO13	721.927
  红霉素	erythromycin	114-07-8	C37H67NO13	733.938
  ——	(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-[3-aminopropyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,10,12,13-tetrahydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one	654076-81-0	C39H74N2O13	779.022
  ——	(9S)-5-O-desosaminyl-9-dihydroerythronolide A	50896-25-8	C29H55NO10	577.756
  ——	(9S)-9-dihydroerythromycin A N-oxide	138505-44-9	C37H69NO14	751.953
  ——	N-[(2S,3R,4S,6R)-2-[[(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2-oxo-oxacyclotetradec-6-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-N-methylacetamide	654076-78-5	C38H69NO14	763.964
  红霉素A氧化物	erythromycin A N-oxide	992-65-4	C37H67NO14	749.937
  ——	2-chloro-N-[(2S,3R,4S,6R)-2-[[(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2-oxo-oxacyclotetradec-6-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-N-methylacetamide	654076-75-2	C38H68ClNO14	798.409
  ——	(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-6-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl-[3-(1,3-thiazol-2-ylmethylamino)propyl]amino]oxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one	654076-82-1	C43H77N3O13S	876.163
  ——	2-[2-(dimethylamino)ethylamino]-N-[(2S,3R,4S,6R)-2-[[(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2-oxo-oxacyclotetradec-6-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-N-methylacetamide	654076-76-3	C42H79N3O14	850.101

反应信息

• 作为反应物：
  描述：

  (9S)-9-dihydroerythromycin A 在 Raney-Ni (W₄) 氢气 、 溴 、 间氯过氧苯甲酸 、 三丁基氧化锡 作用下， 以 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 反应 25.17h， 生成 红霉素
  参考文献：
  名称：

  有效的2,6-脱水-2-硫代糖基糖基化在红霉素A全合成中的应用

  摘要：

  由（9S）-9-二氢赤藓醇内酯A（2）合成红霉素A（I），是通过2,6-脱水-2-硫代糖9的高度立体选择性和强力糖基化作为关键步骤而有效地实现的。

  DOI：

  10.1016/0040-4039(91)80777-4
• 作为产物：
  描述：

  红霉素 在 aluminum oxide 、 sodium tetrahydroborate 作用下， 以82%的产率得到(9S)-9-dihydroerythromycin A
  参考文献：
  名称：

  红霉素的不对称全合成。3. 红霉素的全合成

  摘要：

  在之前的论文中，我们描述了光学活性形式的关键内酯中间体 1a 的制备。在本文中，我们报告了来自 la 的红霉素 (2) 的合成。从本质上讲，这种转化包括用 L-cladinose 和 D-desosamine 对 la 的合适衍生物进行糖苷化，并产生 C-9 酮官能团。

  DOI：

  10.1021/ja00401a051

文献信息

• [EN] 2'-O,3'-N-BRIDGED MACROLIDES<br/>[FR] MACROLIDES 2'-O,3'-N-PONTÉS
  申请人：GLAXOSMITHKLINE ZAGREB

  公开号：WO2009130189A1

  公开（公告）日：2009-10-29

  Novel 2 ' -O, 3 ' -/V-bridged macrolides useful in treatment of inflammatory diseases. More particularly, the invention relates to 2 ' -O, 3 ' -/V-bridged 14- membered macrolides and to 2 ' - O, 3 ' -/V-bridged 15-membered azalide macrolides useful in treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to intermediates for their preparation, to the methods for their preparation, to their use as therapeutic agents, and to salts thereof.

  ' -O, 3 ' -/V-bridged macrolides useful in treatment of inflammatory diseases. More particularly, the invention relates to 2 ' -O, 3 ' -/V-bridged 14- membered macrolides and to 2 ' - O, 3 ' -/V-bridged 15-membered azalide macrolides useful in treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to intermediates for their preparation, to the methods for their preparation, to their use as therapeutic agents, and to salts thereof.
• Motilide compounds
  申请人：Liu Yaoquan

  公开号：US20060270616A1

  公开（公告）日：2006-11-30

  Compounds having a structure according to formula (I) where R A , R B , R C , R D , R E , and R F are as defined herein, are useful as prokinetic agents.

  具有如公式（I）所示结构的化合物，其中RA、RB、RC、RD、RE和RF的定义如本文所述，可用作促动力剂。
• Motilide polymorphs
  申请人：Licari Peter J.

  公开号：US20080146654A1

  公开（公告）日：2008-06-19

  The invention provides polymorphs of a motilide having a structure represented by formula Ia

  这项发明提供了具有由化学式Ia表示的结构的莫替利德的多型体。
• 9-Desoxoerythromycin compounds as prokinetic agents
  申请人：Liu Yaoquan

  公开号：US20050256064A1

  公开（公告）日：2005-11-17

  9-Desoxoerythromycin compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful as prokinetic agents for treating disorders of gastric motility.

  式I中，R1、R2、R3、R4和R5的定义如本文所述，9-脱氧红霉素化合物可用作促动力剂，用于治疗胃动力障碍。
• 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE
  申请人：Sugimoto Tomohiro

  公开号：US20110152239A1

  公开（公告）日：2011-06-23

  The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of the fatty acids with chain length C14 and C 16.

  本发明涉及一种从磷虾制备高浓度ω-3脂肪酸组合物的方法。此外，本发明涉及一种包含高浓度ω-3脂肪酸的组合物，以及从磷虾中提取的含有链长为C14和C16的脂肪酸高含量的脂质分数。